ACA
PVLA

Apis Capital Advisors’s Palvella Therapeutics PVLA Stock Holding History

Apis Capital Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96M Sell
39,000
-50,000
-56% -$6.07M 0.58% 39
2026
Q1 		$11.1M Buy
+89,000
New +$9.28M 1.71% 25
2025
Q4 		– Sell
-10,000
Closed -$627K – 54
2025
Q3 		$627K Buy
+10,000
New +$446K 0.14% 45

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Apis Capital Advisors's PVLA Position: Q2 2026 in Review

Apis Capital Advisors reduced its Palvella Therapeutics (PVLA) stake by 56% in Q2 2026, selling an estimated $6.07M and leaving 39,000 shares worth $5.96M. The position accounts for 0.58% of the portfolio, ranked #39.

Apis Capital Advisors first reported a position in PVLA in Q3 2025 and has held it in 3 quarters since. The position peaked at $11.1M in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Apis Capital Advisors held 39,000 shares of Palvella Therapeutics worth $5.96M as of Q2 2026.
  • Apis Capital Advisors sold 50,000 Palvella Therapeutics shares in Q2 2026, an estimated $6.07M.
  • Palvella Therapeutics made up 0.58% of Apis Capital Advisors's portfolio in Q2 2026, its #39 holding.
  • Apis Capital Advisors first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Apis Capital Advisors's Palvella Therapeutics position peaked at $11.1M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Apis Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.